CA2609985A1 - Modulation of cell barrier dysfunction - Google Patents

Modulation of cell barrier dysfunction Download PDF

Info

Publication number
CA2609985A1
CA2609985A1 CA002609985A CA2609985A CA2609985A1 CA 2609985 A1 CA2609985 A1 CA 2609985A1 CA 002609985 A CA002609985 A CA 002609985A CA 2609985 A CA2609985 A CA 2609985A CA 2609985 A1 CA2609985 A1 CA 2609985A1
Authority
CA
Canada
Prior art keywords
opioid receptor
opioid
aeruginosa
receptor antagonist
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002609985A
Other languages
English (en)
French (fr)
Inventor
John C. Alverdy
Jonathan Moss
Mark W. Lingen
Patrick A. Singleton
Joe G.N. Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/007892 external-priority patent/WO2006096626A2/en
Application filed by Individual filed Critical Individual
Publication of CA2609985A1 publication Critical patent/CA2609985A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002609985A 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction Abandoned CA2609985A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US68756805P 2005-06-03 2005-06-03
US60/687,568 2005-06-03
US73100905P 2005-10-28 2005-10-28
US60/731,009 2005-10-28
US76085106P 2006-01-20 2006-01-20
US60/760,851 2006-01-20
PCT/US2006/007892 WO2006096626A2 (en) 2005-03-07 2006-03-07 Use of opioid antagonists to attenuate endothelial cell proliferation and migration
USPCT/US2006/07892 2006-03-07
PCT/US2006/021604 WO2007053194A2 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction

Publications (1)

Publication Number Publication Date
CA2609985A1 true CA2609985A1 (en) 2007-05-10

Family

ID=38006351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002609985A Abandoned CA2609985A1 (en) 2005-06-03 2006-06-05 Modulation of cell barrier dysfunction

Country Status (3)

Country Link
EP (1) EP1901742A2 (de)
CA (1) CA2609985A1 (de)
WO (1) WO2007053194A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
JP2009534384A (ja) * 2006-04-19 2009-09-24 ジル・ピー・スミス オピオイドアンタゴニストによる炎症性および潰瘍性腸疾患の治療
EP3064503A1 (de) 2007-03-29 2016-09-07 Progenics Pharmaceuticals, Inc. Antagonisten der peripheren opioidrezeptoren und ihre verwendung
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
BRPI0817804A8 (pt) * 2007-10-05 2017-04-18 Toray Industries Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
ES2620373T3 (es) 2008-07-01 2017-06-28 University Of Chicago Partículas que contienen un antagonista del receptor de opioides periférico
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ES2951828T3 (es) 2010-09-23 2023-10-25 Leading Biosciences Inc Administración de inhibidores de serina proteasa al estómago
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
MX2016012248A (es) 2014-03-25 2017-04-27 Leading Biosciences Inc Composiciones para el tratamiento de autodigestion.
CN117940554A (zh) * 2022-06-30 2024-04-26 上海羽冠生物技术有限公司 假单胞菌属的活细菌菌株

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
CA2610951A1 (en) * 2005-06-03 2006-12-14 The University Of Chicago Modulation of microbial pathogen-host cell interactions

Also Published As

Publication number Publication date
EP1901742A2 (de) 2008-03-26
WO2007053194A2 (en) 2007-05-10
WO2007053194A3 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
US20140142133A1 (en) Modulation of cell barrier dysfunction
CA2609985A1 (en) Modulation of cell barrier dysfunction
AU2012272815B2 (en) Treatment of proteinopathies
US9393221B2 (en) Methods and compounds for reducing intracellular lipid storage
Ye et al. Scutellarin inhibits caspase-11 activation and pyroptosis in macrophages via regulating PKA signaling
AU2006255274A1 (en) Modulation of microbial pathogen-host cell interactions
EP2285366B1 (de) Moleküle als hemmer eines stoffwechselweges umfassend die syk-proteintyrosinkinase und verfahren zur identifizierung derartiger moleküle
JP5078885B2 (ja) Flt3阻害剤とファルネシル転移酵素阻害剤を用いたflt3キナーゼの相乗的モジュレーション
Urbauer et al. Mitochondrial metabolism in the intestinal stem cell niche—sensing and signaling in health and disease
AU2003221767B2 (en) Synergistic effects of nuclear transcription factor NF-kB inhibitors and anti-neoplastic agents
AU2006341983A1 (en) Use of an NMDA receptor antagonist the treatment of tinnitus induced by cochlear excitotoxicity
CN108366997A (zh) 治疗痛觉过敏的方法
JP2019513749A (ja) 衛生化及び麻酔用のtrpv4及びtrpa1の小分子二重阻害剤
US20090186949A1 (en) Method for Treating Endothelial and Epithelial Cell Disorders by Administering High Molecular Weight PEG-Like Compounds
Wang et al. Chaperone heat shock protein 70 in nucleus accumbens core: a novel biological target of behavioural sensitization to morphine in rats
WO2019246298A1 (en) Compositions and methods for the reduction or treatment of fibrosis
EP3610869A1 (de) Zusammensetzung, enthaltend sarpogrelat als wirkstoff, zur prävention oder behandlung von sensorineuronalem hörverlust
Shimazu et al. (−)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release
KR20100015085A (ko) 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
KR20220041134A (ko) 세로토닌성 제제 및 5-ht1a-수용체 길항제
JP2007504181A (ja) セロトニン再取り込み阻害剤およびロキサピンの併用
TW201529066A (zh) 牛樟芝化合物及其用於治療糖尿病的方法
EP2599488B1 (de) Vicenin 2 und Derivate davon zur Verwendung als Antispasmodikum und/oder Prokinetikum
NO20062810L (no) Fast farmasoytisk preparatform
KR20230019387A (ko) 호노키올을 포함하는 조성물 및 이의 내피 기능장애 질환의 예방, 개선 및 치료 용도

Legal Events

Date Code Title Description
FZDE Dead